- Home
- GYRE vs NBTX Comparison
GYRE vs NBTX Comparison
Compare GYRE & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- NBTX
- Stock Information
- Founded
- GYRE 2002
- NBTX 2003
- Country
- GYRE United States
- NBTX France
- Employees
- GYRE N/A
- NBTX N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- GYRE Health Care
- NBTX Health Care
- Exchange
- GYRE Nasdaq
- NBTX Nasdaq
- Market Cap
- GYRE 897.1M
- NBTX 868.8M
- IPO Year
- GYRE N/A
- NBTX 2020
- Fundamental
- Price
- GYRE $7.28
- NBTX $20.65
- Analyst Decision
- GYRE Strong Buy
- NBTX Strong Buy
- Analyst Count
- GYRE 1
- NBTX 1
- Target Price
- GYRE $18.00
- NBTX $8.00
- AVG Volume (30 Days)
- GYRE 92.0K
- NBTX 119.0K
- Earning Date
- GYRE 11-12-2025
- NBTX 09-30-2025
- Dividend Yield
- GYRE N/A
- NBTX N/A
- EPS Growth
- GYRE N/A
- NBTX N/A
- EPS
- GYRE 0.02
- NBTX N/A
- Revenue
- GYRE $102,189,000.00
- NBTX $11,930,711.00
- Revenue This Year
- GYRE $16.80
- NBTX N/A
- Revenue Next Year
- GYRE $50.29
- NBTX $74.67
- P/E Ratio
- GYRE $428.23
- NBTX N/A
- Revenue Growth
- GYRE N/A
- NBTX N/A
- 52 Week Low
- GYRE $6.11
- NBTX $2.76
- 52 Week High
- GYRE $19.00
- NBTX $22.85
- Technical
- Relative Strength Index (RSI)
- GYRE 44.66
- NBTX 72.61
- Support Level
- GYRE $7.20
- NBTX $19.11
- Resistance Level
- GYRE $7.72
- NBTX $22.64
- Average True Range (ATR)
- GYRE 0.28
- NBTX 1.64
- MACD
- GYRE -0.01
- NBTX 0.64
- Stochastic Oscillator
- GYRE 28.58
- NBTX 84.58
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.